Diagnostic Antibodies
Diagnostic Antibodies - Related Videos
08:53
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
0 Views •
Cited by 1 •
2019
The in vivo immunofluorescence localization (IVIL) method can be used to examine in vivo biodistribution of antibodies and antibody conjugates for oncological purposes in living organisms using a combination of in vivo tumor targeting and ex vivo immunostaining methods.
10:21
Microfluidic Applications for Disposable Diagnostics
0 Views •
Cited by 1 •
2008
In this interview, Dr. Klapperich discusses the fabrication of thermoplastic microfluidic devices and their application for development of new diagnostics.
13:01
Anti-Nuclear Antibody Screening Using HEp-2 Cells
0 Views •
Cited by 34 •
2014
Indirect immunofluorescent (IIF) assays have traditionally been used for the detection of antinuclear antibodies (ANA) in human serum. The presence of these antibodies can aid in the diagnosis of systemic autoimmune rheumatic diseases (SARD). This protocol demonstrates how to effectively perform the IIF technique to accurately detect these autoantibodies.
21:15
Diagnostic Necropsy and Tissue Harvest
0 Views •
2016
Source: Kay Stewart, RVT, RLATG, CMAR; Valerie A. Schroeder, RVT, RLATG. University of Notre Dame, IN Many animal experiments rely on final data collection time points that are gathered from the harvesting and testing of organs and tissues. The use of appropriate methods for the collection of organs and tissues can impact the quality of the samples and the analysis of the data that is gleaned for the testing of the tissues. The method of euthanasia of the animal can also impact the quality of...
13:21
Antibody Generation: Producing Monoclonal Antibodies Using Hybridomas
0 Views •
2023
Source: Frances V. Sjaastad1,2, Whitney Swanson2,3, and Thomas S. Griffith1,2,3,4 1 Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, MN 55455 2 Center for Immunology, University of Minnesota, Minneapolis, MN 55455 3 Department of Urology, University of Minnesota, Minneapolis, MN 55455 4 Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455 Polyclonal antibodies are defined as a collection of antibodies directed against...
FAQs
Specificity comes from molecular complementarity: an antibody binds a matching antigen rather than unrelated molecules. In cancer samples, that selectivity links the detected signal to a tumor-associated protein. Researchers can therefore use the resulting molecular pattern to support disease classification, biomarker analysis, and comparisons among tumor cell populations.
Detection systems convert antibody binding into an observable or measurable result. Depending on the assay, labels, enzymes, fluorescence, or other detection systems can indicate where binding occurred or how much signal was produced. This conversion allows researchers to analyze target molecules rather than relying on molecular recognition alone, strengthening the practical value of the test.
Specificity is important because cancer samples can contain different biological molecules and cell types. Binding directed toward a selected tumor-associated protein helps separate disease-related findings from less relevant signals. This supports clearer tumor characterization, more reliable diagnostic-test development, and research strategies tailored to the molecular features being examined.
Immunohistochemistry applies antibody-based recognition to characterize tumor cells in the sample being examined. By detecting selected tumor-associated proteins with a visualizable system, the method can contribute to disease classification and identification of disease subtypes. Its value lies in connecting molecular targets with features observed in the cancer specimen.
Flow cytometry is one of the antibody-based applications used in cancer studies to examine characteristics associated with tumor cells. Diagnostic antibodies identify selected molecular features, and the resulting signals support cell characterization. This approach can complement other methods when researchers need to distinguish disease subtypes or compare tumor-cell populations.
These approaches are useful when cancer research requires measured evidence about selected biomarkers. Immunoassays provide a detection format for antibody-based measurement, while biomarker analysis organizes the resulting information for study. Together, they can support disease characterization and evaluation of treatment responses, linking detected molecular features with research questions.
By identifying molecular features associated with tumor cells, diagnostic antibodies can supply information for research strategies that reflect differences among disease subtypes or biomarker patterns. Their specificity also supports development of more reliable diagnostic tests. In this way, antibody-based findings connect tumor characterization with selection of biological features for further study.